Study identifier:NIS-NKR-SER-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Effectiveness of atypical antipsychotics on anhedonic features in patients with schizophrenia
schizophrenia
-
No
-
All
231
Observational
20 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting. There will be no experimental component associated with this study and all observational activities have to be part of routine care visit: baseline (week 0), week 4 and week 12.
Location
Location
Anyang-si, Gyeonggi-do, Republic of Korea
Location
Bucheon, Gyeonggi-do, Republic of Korea
Location
Busan, Busan, Republic of Korea
Location
Changnyeong-gun, Gyeongsangnam-do, Republic of Korea
Location
Chuncheon, Gangwon-do, Republic of Korea
Location
Daegu, Daegu, Republic of Korea
Location
Daejeon, Daejeon, Republic of Korea
Location
Gongju-si, Chungcheongnam-do, Republic of Korea
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.